‹ Screener

COSCIENS Biopharma Inc.

CSCIF · Perfumes, Cosmetics & Other Toilet Preparations · EDGAR filings ↗

Grade

D45

gen composite 15pct→48; net margin <-100%; net + operating loss

Notable findings

Quarterly revenue

2025-03-31 · $2M2025-06-30 · $3M2025-09-30 · $1M2025-12-31 · $2M

Last 4 quarters · from SEC filings.

Supply chain

Customers (1)

  • Symrise AG 84% of rev

Suppliers (0)

    Named in the 10-K; linked when we track them.

    Key metrics

    Gross margin
    35.3%
    Operating margin
    -142.5%
    Net margin
    -138.1%
    Return on equity
    -269.6%
    Return on assets
    -48.3%
    ROIC
    -219.6%
    Revenue growth (QoQ)
    -46.8%
    Interest coverage
    -63.6×
    Current ratio
    3.2×
    Free cash flow
    -$9M
    EBITDA
    -$9M
    Tangible book value
    $4M
    Cash & investments
    $7M
    Cash runway
    3q

    Recent filings

    FormFiledPeriodAccession
    20-F2026-03-252025-12-310001493152-26-012703 ↗
    20-F2025-04-092024-12-310001641172-25-003456 ↗
    20-F2024-03-272023-12-310001493152-24-011401 ↗
    20-F2023-03-232022-12-310001493152-23-008641 ↗
    20-F2022-03-292021-12-310001493152-22-007933 ↗
    40-F2021-03-252020-12-310001493152-21-006745 ↗
    20-F2020-03-312019-12-310001493152-20-005347 ↗
    20-F2019-04-012018-12-310001628280-19-003681 ↗
    20-F2018-03-282017-12-310001628280-18-003635 ↗
    20-F2017-03-162016-12-310001113423-17-000010 ↗
    20-F2016-03-302015-12-310001113423-16-000039 ↗
    20-F2015-03-172015-03-170001113423-15-000004 ↗